Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1957 1
1958 1
1959 1
1960 1
1962 2
1963 2
1964 3
1965 4
1966 3
1967 5
1968 7
1969 9
1970 4
1971 4
1972 4
1973 4
1974 8
1975 10
1976 7
1977 8
1978 11
1979 8
1980 8
1981 8
1982 7
1983 8
1984 21
1985 16
1986 15
1987 22
1988 33
1989 32
1990 34
1991 30
1992 35
1993 47
1994 52
1995 75
1996 79
1997 110
1998 138
1999 152
2000 162
2001 234
2002 280
2003 353
2004 427
2005 554
2006 645
2007 789
2008 886
2009 1046
2010 1328
2011 1588
2012 1717
2013 1868
2014 2002
2015 2143
2016 2113
2017 2070
2018 2019
2019 2061
2020 2186
2021 2443
2022 2179
2023 2037
2024 2018
2025 195

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32,206 results

Results by year

Filters applied: . Clear all
Page 1
KAAACI Guidelines for Allergen Immunotherapy.
Lee HY, Lee SM, Kang SY, Kim K, Kim JH, Ryu G, Min JY, Park KH, Park SY, Sung M, Lee Y, Yang EA, Jee HM, Ha EK, Shin YS, Chung EH, Choi SH, Koh YI, Kim ST, Nahm DH, Park JW, Shim JY, An YM, Han DH, Han MY, Lee YW, Choi JH; Korean Academy of Asthma Allergy and Clinical Immunology (KAAACI) Allergen Immunotherapy and Allergen Working Group. Lee HY, et al. Among authors: kim jh. Allergy Asthma Immunol Res. 2023 Nov;15(6):725-756. doi: 10.4168/aair.2023.15.6.725. Allergy Asthma Immunol Res. 2023. PMID: 37957792 Free PMC article. Review.
Preclinical, randomized phase 1, and compassionate use evaluation of REGN4461, a leptin receptor agonist antibody for leptin deficiency.
Altarejos JY, Pangilinan J, Podgrabinska S, Akinci B, Foss-Freitas M, Neidert AH, Ray Y, Zheng W, Kim S, Kamat V, Huang M, Min S, Mastaitis J, Dominguez-Gutierrez G, Kim JH, Stevis P, Huang T, Zambrowicz B, Olson WC, Godin S, Bradley E, Gewitz AD, Baker M, Hench R, Davenport MS, Chenevert TL, DiPaola F, Yancopoulos GD, Murphy AJ, Herman GA, Musser BJ, Dansky H, Harp J, Gromada J, Sleeman MW, Oral EA, Olenchock BA. Altarejos JY, et al. Among authors: kim jh. Sci Transl Med. 2023 Nov 22;15(723):eadd4897. doi: 10.1126/scitranslmed.add4897. Epub 2023 Nov 22. Sci Transl Med. 2023. PMID: 37992152 Clinical Trial.
Should we ban TOT? - Cons.
Tak Oh K, Oh M, Shim JS, Kim JH. Tak Oh K, et al. Among authors: kim jh. Fr J Urol. 2024 Nov;34(10):102793. doi: 10.1016/j.fjurol.2024.102793. Fr J Urol. 2024. PMID: 39477654 No abstract available.
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.
Drew Y, Kim JW, Penson RT, O'Malley DM, Parkinson C, Roxburgh P, Plummer R, Im SA, Imbimbo M, Ferguson M, Rosengarten O, Steeghs N, Kim MH, Gal-Yam E, Tsoref D, Kim JH, You B, De Jonge M, Lalisang R, Gort E, Bastian S, Meyer K, Feeney L, Baker N, Ah-See ML, Domchek SM, Banerjee S; MEDIOLA Investigators. Drew Y, et al. Among authors: kim jh. Clin Cancer Res. 2024 Jan 5;30(1):50-62. doi: 10.1158/1078-0432.CCR-23-2249. Clin Cancer Res. 2024. PMID: 37939124 Free PMC article. Clinical Trial.
32,206 results
You have reached the last available page of results. Please see the User Guide for more information.